|
시장보고서
상품코드
2091885
티카그렐러 시장 규모, 점유율 및 성장 분석 : 적응증별, 환자 유형별, 약제 유형별, 처방 유형별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Ticagrelor Market Size, Share, and Growth Analysis, By Indication, By Patient Type, By Drug Type, By Prescription Type, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 티카그렐러 시장 규모는 2024년에 18억 8,000만 달러로 평가되며, 2025년 19억 9,000만 달러에서 2033년까지 31억 5,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.9%로 성장할 것으로 전망되고 있습니다.
현재 전 세계 티카그렐러 시장은 가격 책정의 유연성과 적응증 확장에 힘입어 성장하고 있으며, 이러한 요인들은 수익 잠재력을 높이는 동시에 지불 주체의 거부감을 완화시키고 있습니다. 레지스트리 자료에 따르면 만성 관상동맥 증후군 환자에게 치카그렐롤을 투여할 경우 재입원율이 크게 감소하는 것으로 나타났으며, 이에 따라 중국과 브라질 보건부는 해당 약물을 국가 표준 처방집에 포함시켰습니다. 이러한 정책 전환으로 인해 소비자의 부담이 효과적으로 경감되고, 의사의 처방 채택이 촉진되는 한편, 제조사의 생산량도 증가하고 있습니다. 유럽에서 제네릭 의약품의 도입은 오리지널 제약사에 압박을 가하고 있으며, 보다 간편한 치료 요법이 필요한 고령 환자에 대응하기 위해 고정 용량 복합제의 개발이 촉진되고 있습니다. 이 경구용 P2Y12 수용체 길항제는 심혈관 사건 예방에 있으며, 클로피도그렐보다 우수한 것으로 입증됨에 따라 그 사용이 지속적으로 증가하고 있으며, 투자자들의 관심을 끌고 있을 뿐만 아니라 혁신적인 제형 및 보험 급여 전략에 대한 논의를 촉발하고 있습니다.
세계 티카그렐러 시장의 성장 요인
전 세계에서 동맥경화성 심혈관 질환의 유병률이 증가하고 있는 만큼, 의료 서비스 제공자들은 보다 효과적인 항혈소판 요법의 도입을 서둘러야 하는 상황에 놓여 있습니다. 치카그렐롤의 혈소판 응집 억제 능력은 급성 관상동맥 증후군 관리에 관한 현행 임상 지침에 부합하며, 기존 약물보다 우선적으로 선택되고 있습니다. 이러한 치료상의 장점은 임상의들의 신뢰를 높여, 다양한 의료 환경에서 이 치료에 적합한 환자층을 확대하고 있습니다. 그 결과, 병원과 심혈관 클리닉에서는 치료 프로토콜에 치카그렐롤을 점진적으로 도입하고 있으며, 이는 해당 약물의 시장 입지를 강화하고 수요의 지속적인 성장을 촉진하고 있습니다. 또한 치료 성과에 대한 환자들의 인식이 높아진 점도 임상의들의 선호를 지원하며 시장 확대에 기여하고 있습니다.
세계 티카그렐러 시장의 제약 요인
전 세계 티카그렐러 시장은 주로 제네릭 항혈소판제에 비해 가격이 비싸기 때문에 병원과 보험사에 재정적 부담을 안겨준다는 큰 제약에 직면해 있습니다. 지급 기관은 보험 적용을 승인하기 전에 포괄적인 약제경제학적 근거를 요구하는 경우가 많으며, 그 결과 의약품이 보험 적용 리스트에 등재되는 것이 지연될 수 있습니다. 이러한 환급 관련 문제는 특히 가격에 민감한 지역에서 환자의 접근성을 제한하고 있으며, 치카그렐롤의 임상적 이점에도 불구하고 의료 서비스 제공자들이 더 저렴한 대체 약물을 선택하게 만드는 원인이 되고 있습니다. 그 결과, 가격에 대한 민감성과 복잡한 상환 협상이 다양한 의료제도에서의 광범위한 도입을 제한하고 있으며, 시장의 성장 가능성이 저해되고 있습니다. 또한 가격 협상이 장기화되면 계약 체결이 지연되어, 새로운 지역으로의 시장 확대가 더욱 저해될 가능성이 있습니다.
세계 티카그렐러 시장의 동향
전 세계 티카그렐러 시장에서는 임상의들이 다모달 치료 요법을 점점 더 중시함에 따라 새로운 병용 요법에 대한 뚜렷한 추세가 나타나고 있습니다. 의료진은 티카그렐러를 PCSK9 억제제, 항응고제, 항염증약 등 혁신적인 약물과 병용함으로써, 특히 복잡한 플라크 특징이나 염증 지표의 상승이 관찰되는 환자에서 잔존하는 심혈관 위험을 관리하는 것을 목표로 하고 있습니다. 이러한 전략적 접근을 통해 치카그렐롤의 임상 적용 범위는 표준적인 급성 관상동맥 증후군 치료 프로토콜을 넘어 확대되었으며, 만성기 관리 체계로의 통합이 촉진되고 있습니다. 또한 이러한 추세는 다양한 의료 전문 분야에 걸친 공동 연구를 촉진하고, 순환기학, 신경학, 대사 질환 전문가들 간의 학제 간 대화를 심화시키고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 티카그렐러 시장 규모 : 적응증별
세계의 티카그렐러 시장 규모 : 환자 유형별
세계의 티카그렐러 시장 규모 : 약제 유형별
세계의 티카그렐러 시장 규모 : 처방 형태별
세계의 티카그렐러 시장 규모 : 유통 채널별
세계의 티카그렐러 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Ticagrelor Market size was valued at USD 1.88 Billion in 2024 and is poised to grow from USD 1.99 Billion in 2025 to USD 3.15 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).
The global ticagrelor market is currently driven by pricing flexibility and expanded indications, which enhance revenue potential while mitigating payer resistance. Evidence from registries indicates that utilizing ticagrelor in chronic coronary syndrome significantly lowers rehospitalization rates, prompting health ministries in China and Brazil to include it in their national formularies. This policy shift effectively decreases consumer costs, boosting physician adoption and increasing production volume for manufacturers. The introduction of generics in Europe places pressure on original developers, encouraging the creation of fixed-dose combinations to cater to elderly patients needing simpler treatment regimens. As the oral P2Y12 receptor antagonist demonstrates superiority over clopidogrel in preventing cardiovascular events, its uptake continues to rise, attracting investor interest and prompting discussions on innovative formulations and reimbursement strategies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ticagrelor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ticagrelor Market Segments Analysis
Global ticagrelor market is segmented by indication, patient type, drug type, prescription type, distribution channel and region. Based on indication, the market is segmented into Acute Coronary Syndrome (ACS), Myocardial Infarction (MI), Ischemic Stroke & Transient Ischemic Attack (TIA), Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD) and Others. Based on patient type, the market is segmented into Adult and Geriatric. Based on drug type, the market is segmented into Branded Ticagrelor and Generic Ticagrelor. Based on prescription type, the market is segmented into Inpatient Prescription and Outpatient Prescription. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ticagrelor Market
The increasing global prevalence of atherosclerotic cardiovascular diseases is motivating healthcare providers to implement more effective antiplatelet therapies. Ticagrelor's enhanced ability to inhibit platelet aggregation aligns with current clinical guidelines for managing acute coronary syndrome, making it a preferred choice over traditional medications. This therapeutic benefit boosts clinician confidence and broadens the range of patients who are suited for this treatment across various healthcare environments. As a result, hospitals and cardiology clinics are progressively integrating ticagrelor into their treatment protocols, which strengthens its market presence and fosters sustained growth in demand. Furthermore, heightened patient awareness regarding treatment outcomes further supports clinician preferences and contributes to market expansion.
Restraints in the Global Ticagrelor Market
The Global Ticagrelor market faces significant constraints primarily due to its higher price compared to generic antiplatelet medications, which places financial strain on hospitals and insurance companies. Payers often require comprehensive pharmacoeconomic evidence before approving coverage, resulting in delays in the drug's formulary inclusion. This reimbursement challenge restricts patient access, particularly in price-sensitive regions, leading healthcare providers to opt for lower-cost alternatives despite Ticagrelor's clinical benefits. Consequently, the market's growth potential is hindered as price sensitivity and complex reimbursement negotiations limit broader adoption across various healthcare systems. Additionally, prolonged price negotiations can delay contract finalization, further impeding market expansion into new areas.
Market Trends of the Global Ticagrelor Market
The Global Ticagrelor market is witnessing a significant trend toward emerging combination therapies, as clinicians increasingly prioritize multimodal treatment regimens. By combining ticagrelor with innovative agents such as PCSK9 inhibitors, anticoagulants, and anti-inflammatory drugs, healthcare providers aim to tackle residual cardiovascular risks, particularly in patients exhibiting complex plaque characteristics or elevated inflammatory markers. This strategic approach broadens the clinical applications of ticagrelor beyond standard acute coronary syndrome protocols, propelling its integration into chronic management frameworks. Additionally, this trend catalyzes collaborative research efforts across various medical specialties, enhancing interdisciplinary dialogue among experts in cardiology, neurology, and metabolic diseases.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Ticagrelor Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Acute Coronary Syndrome (ACS)
- Myocardial Infarction (MI)
- Ischemic Stroke & Transient Ischemic Attack (TIA)
- Coronary Artery Disease (CAD)
- Peripheral Artery Disease (PAD)
- Others
Global Ticagrelor Market Size by Patient Type & CAGR (2026-2033)
- Market Overview
- Adult
- Geriatric
Global Ticagrelor Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Branded Ticagrelor
- Generic Ticagrelor
Global Ticagrelor Market Size by Prescription Type & CAGR (2026-2033)
- Market Overview
- Inpatient Prescription
- Outpatient Prescription
Global Ticagrelor Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Homecare Settings
Global Ticagrelor Market Size & CAGR (2026-2033)
- North America (Indication, Patient Type, Drug Type, Prescription Type, Distribution Channel)
- US
- Canada
- Europe (Indication, Patient Type, Drug Type, Prescription Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Patient Type, Drug Type, Prescription Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Patient Type, Drug Type, Prescription Type, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Patient Type, Drug Type, Prescription Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alembic Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taro Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macleods Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ascend Laboratories, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novadoz Pharmaceuticals LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hisun Pharmaceutical (Hangzhou) Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
